SinoBioData Academic Portal
ZC
Verified CAS / Academic Author2 Decoded Studies

Prof. ZHOU Chengming

Nanjing Medical University, The Affiliated Huai'an No.1 People's Hospital

Research Publications & English Decoded Briefs

Showing 2 publications
Acta Biochimica et Biophysica Sinica2025DOI: 10.3724/abbs.2025093

Modulation of ferroptosis via YY1-SLC7A11 axis in hepatic ischemia-reperfusion injury pathogenesis

YY1 is a crucial transcription factor and plays significant roles in biological processes. However, the mechanisms of YY1 action in ischemia-reperfusion injury and its regulatory role in ferroptosis have not been extensively studied. This study aims to elucidate the molecular mechanism by which NEDD4L-mediated degradation of YY1 through ubiquitination suppresses SLC7A11 transcription, leading to the promotion of cellular ferroptosis and exacerbation of hepatic ischemia-reperfusion injury (IRI), via the integration of multiple omics sequencing datasets. An IRI-I/R mouse model is established, followed by proteomic sequencing to identify proteins that are differentially expressed during IRI. The altered expression of YY1 is validated, and in vivo and in vitro experiments are used to assess its impact on IRI damage. The E3 ligase NEDD4L, which regulates YY1 ubiquitination, is identified and validated via the UbiBrowser 2.0 database. The ubiquitination types of YY1 and its sites are screened and confirmed through in vitro experiments. Transcriptional sequencing of YY1-overexpressing cell lines is conducted to analyze the involvement of the downstream transcription factor SLC7A11 in IRI, followed by validation of its regulatory role. The results show that YY1 is downregulated in liver tissues during IRI and is expressed primarily in liver cells. YY1 overexpression alleviates liver tissue and liver cell IRI both in vitro and in vivo. Upregulation of E3 ligase expression during IRI promotes the K63-linked ubiquitination of YY1 at the K339 site, leading to proteasomal degradation of YY1. RNA-seq analysis and experimental validation demonstrate that YY1 suppresses IRI-induced ferroptosis via the transcriptional regulation of downstream target genes. YY1 positively regulates SLC7A11 transcription, inhibits IRI-induced ferroptosis and ameliorates liver injury. In summary, the E3 ubiquitin ligase NEDD4L facilitates YY1 protein degradation through ubiquitination, suppressing the transcription of the ferroptosis inhibitor SLC7A11, thus promoting IRI-related ferroptosis and exacerbating liver injury.

Acta Biochimica et Biophysica Sinica2025DOI: 10.3724/abbs.2025093

Modulation of Ferroptosis via the YY1-SLC7A11 Axis in Hepatic Ischemia-Reperfusion Injury Pathogenesis

Hepatic ischemia-reperfusion injury (IRI) remains a major clinical challenge in liver transplantation and resection, with ferroptosis emerging as a critical cell death modality. This study investigates the mechanistic role of the transcription factor YY1 and its regulation by the E3 ubiquitin ligase NEDD4L in hepatic IRI. Using an established mouse IRI model and proteomic sequencing, YY1 was identified as significantly downregulated in injured liver tissues, predominantly in hepatocytes. In vivo and in vitro overexpression of YY1 attenuated IRI-induced liver damage and ferroptosis. Mechanistically, NEDD4L, an E3 ligase upregulated during IRI, was found to interact with YY1 and catalyze K63-linked ubiquitination at lysine 339, leading to proteasomal degradation of YY1. Transcriptomic analysis and validation revealed that YY1 positively regulates the transcription of SLC7A11, a key ferroptosis inhibitor. Consequently, NEDD4L-mediated degradation of YY1 suppresses SLC7A11 expression, promoting ferroptosis and exacerbating hepatic injury. These findings delineate a novel NEDD4L-YY1-SLC7A11 axis in IRI pathogenesis, offering potential therapeutic targets. The study acknowledges limitations, including the need for validation in human liver samples and further in vivo confirmation of some in vitro findings. This research provides a mechanistic framework for developing targeted interventions against hepatic IRI.